A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19

The COVID-19 pandemic and the need for additional safe, effective, and affordable vaccines gave new impetus into development of vaccine genetic platforms. Here we report the findings from the phase 1, first-in-human, dose-escalation study of COVID-eVax, a DNA vaccine encoding the receptor binding do...

Descripción completa

Detalles Bibliográficos
Autores principales: Aurisicchio, Luigi, Brambilla, Nadia, Cazzaniga, Marina E., Bonfanti, Paolo, Milleri, Stefano, Ascierto, Paolo A., Capici, Serena, Vitalini, Cristina, Girolami, Federica, Giacovelli, Giampaolo, Caselli, Gianfranco, Visintin, Michela, Fanti, Francesca, Ghirri, Matteo, Conforti, Antonella, Compagnone, Mirco, Lione, Lucia, Salvatori, Erika, Pinto, Eleonora, Muzi, Alessia, Marra, Emanuele, Palombo, Fabio, Roscilli, Giuseppe, Manenti, Alessandro, Montomoli, Emanuele, Cadossi, Matteo, Rovati, Lucio C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792419/
https://www.ncbi.nlm.nih.gov/pubmed/36575794
http://dx.doi.org/10.1016/j.ymthe.2022.12.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792419/
https://www.ncbi.nlm.nih.gov/pubmed/36575794
http://dx.doi.org/10.1016/j.ymthe.2022.12.017

Ejemplares similares